Restor3d announced today that it completed its previously announced acquisition of Conformis (Nasdaq:CFMS). The companies completed the deal, announced in June, after Conformis’ stockholders approved it at a special meeting on Aug. 31. As a result, shares of Conformis common stock ceased trading on the Nasdaq prior to market open today, Sept. 5. Per the […]
conformis
Restor3d to acquire Conformis for $2.27 per share
Restor3d and Conformis (Nasdaq:CFMS) announced that they entered into a definitive merger agreement. Under the agreement, Restor3d, a 3D-printed orthopedic implants company, acquires all outstanding shares of Conformis common stock. The deal includes a purchase price of $2.27 per share. That represents a 96% premium to the closing price on June 22, 2023. Restor3d intends […]
Conformis stock rises on Street-beating Q1
Conformis shares ticked up today on first-quarter results that came in ahead of the consensus forecast. Shares of CFMS rose more than 1% at $1.36 per share by afternoon trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — fell slightly. The Billerica, Massachusetts-based orthopedic device maker […]
Conformis stock ticks up on Street-beating Q4 revenues
Conformis (Nasdaq:CFMS) shares rose today on fourth-quarter results that came in ahead of the consensus sales forecast. Shares of CFMS ticked up 1.7% to $1.75 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 0.4%. The Billerica, Massachusetts-based orthopedic device maker posted […]
Conformis regains compliance with Nasdaq listing requirement
Conformis (Nasdaq:CFMS) announced today that it regained compliance with the Nasdaq market’s minimum bid price rule. Billerica, Massachusetts-based maker of customized knee and hip replacements received a letter from the market notifying it of regained compliance on Nov. 25. The letter said that the closing price of the company’s common stock registered at $1 per […]
Conformis announces first implants of Actera hip system
Conformis (Nasdaq:CFMS) today announced the first procedure performed with its new Actera hip system for hip reconstruction. Billerica, Massachusetts–based Conformis designed its Actera hip system with a cutting-edge, tri-taper stem. It features a range of sizes and angles derived from Conformis’ deep data analytics of its patient database. The cementless hip stem component also includes […]
Conformis launches made-to-measure Imprint knee system
Conformis (Nasdaq:CFMS) today announced the full commercial launch of its new Imprint knee system. The orthopedic device company designed the Imprint system as made-to-measure. It will become Conformis’ primary knee offering. In addition, the company is offering a fully personalized iTotal Identity system. It’s a deluxe services upgrade option for patients through its Image-to-Implant Platinum Services […]
Conformis reports sales loss of 3% in Q3 results
Conformis (Nasdaq:CFMS) today posted third-quarter results that missed the earnings consensus on Wall Street but beat revenue estimates. The Billerica, Massachusetts-based orthopedic device company reported losses of $15.2 million, or 8¢ per share, on sales of $13.78 million for the three months ended September 30 for a sales loss of 3.29% compared with Q3 2021. […]
Conformis wins FDA clearance for Actera hip system
Conformis (Nasdaq:CFMS) announced yesterday that it received FDA 510(k) clearance for its Actera hip system. Billerica, Massachusetts–based Conformis announced the regulatory win after the market closed on Tuesday, Sept. 13. This afternoon (Wednesday, Sept. 14), shares of CFMS are up 8.5% at 29¢ apiece. The company designed Actera with a tri-taper femoral stem, adding to […]
Conformis rises on in-line Q2 results
Conformis (Nasdaq:CFMS) this week posted second-quarter results that were in line with the consensus on Wall Street. The Billerica, Massachusetts-based orthopedic purveyor reported losses of $15.52 million, or -9¢ per share, on sales of $15.14 million for the three months ended June 30, for a bottom-line loss compared to net income of $38 million in Q2 […]
Conformis posts mixed bag Q1 results, grows sales 12%
Conformis (Nasdaq:CFMS) this week posted first-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Billerica, Massachusetts-based orthopedic device maker reported losses of $16 million, or -9¢ per share, on sales of $15.6 million for three months ended March 31, for a sales growth of 12.4% compared with Q1 2021. […]
